Han Zhen-Xia, Shi Qing, Wang Da-Kun, Li Dong, Lyu Ming
Department of Cadre Health, Qilu Hospital of Shandong University, Jinan 250005, Shandong Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Oct;21(5):1248-55. doi: 10.7534/j.issn.1009-2137.2013.05.033.
Bone marrow (BM) and umbilical cord (UC) are the major sources of mesenchymal stem cells for therapeutics. This study was aimed to compare the basic biologic characteristics of bone marrow-derived and umbilical cord derived-mesenchymal stem cells (BM-MSC and UC-MSC) and their immunosuppressive capability in vitro. The BM-MSC and UC-MSC were cultured and amplified under same culture condition. The growth kinetics, phenotypic characteristics and immunosuppressive effects of UC-MSC were compared with those of BM-MSC.Gene chip was used to compare the genes differentially expressed between UC-MSC and BM-MSC. The results showed that UC-MSC shared most of the characteristics of BM-MSC, including morphology and immunophenotype. UC-MSC could be ready expanded for 30 passages without visible changes. However, BM-MSC grew slowly, and the mean doubling time increased notably after passage 6. Both UC-MSC and BM-MSC could inhibit phytohemagglutinin-stimulated peripheral blood mononuclear cell proliferation, in which BM-MSC mediated more inhibitory effect. Compared with UC-MSC, BM-MSC expressed more genes associated with immune response. Meanwhile, the categories of up-regulated genes in UC-MSC were concentrated in organ development and growth. It is concluded that the higher proliferation capacity, low human leukocyte antigen-ABC expression and immunosuppression make UC-MSC an excellent alternative to BM-MSC for cell therapy. The differences between BM-MSC and UC-MSC gene expressions can be explained by their ontogeny and different microenvironment in origin tissue. These differences can affect their efficacy in different therapeutic applications.
骨髓(BM)和脐带(UC)是治疗用间充质干细胞的主要来源。本研究旨在比较骨髓来源和脐带来源的间充质干细胞(BM-MSC和UC-MSC)的基本生物学特性及其体外免疫抑制能力。在相同培养条件下培养和扩增BM-MSC和UC-MSC。将UC-MSC的生长动力学、表型特征和免疫抑制作用与BM-MSC进行比较。使用基因芯片比较UC-MSC和BM-MSC之间差异表达的基因。结果表明,UC-MSC具有BM-MSC的大部分特征,包括形态和免疫表型。UC-MSC可以顺利传代30次而无明显变化。然而,BM-MSC生长缓慢,传代6次后平均倍增时间显著增加。UC-MSC和BM-MSC均能抑制植物血凝素刺激的外周血单个核细胞增殖,其中BM-MSC介导的抑制作用更强。与UC-MSC相比,BM-MSC表达更多与免疫反应相关的基因。同时,UC-MSC中上调基因的类别集中在器官发育和生长方面。结论是,UC-MSC具有较高的增殖能力、低人类白细胞抗原ABC表达和免疫抑制作用,使其成为细胞治疗中BM-MSC的优秀替代品。BM-MSC和UC-MSC基因表达的差异可以通过它们的个体发生以及起源组织中不同的微环境来解释。这些差异会影响它们在不同治疗应用中的疗效。